インドの総合的な乳がん治療プログラムで乳がんの初期段階の患者の 10 年生存率

Priyansh Nathani^1,2, Parth Tailor³, Prashant Bhandarkar⁴

¹World Health Organization Collaborating Centre for Emergency, Critical and Operative Care, Program for Global Surgery & Trauma, The George Institute for Global Health, New Delhi, India.

Frontiers in public health

|September 4, 2025

まとめ

乳がんの早期発見はインドの生存率を大幅に改善します全国民健康保険の包括的なプログラムにより,5年および10年生存率は全国平均を超えました.

科学分野:

腫瘍学
公衆衛生
流行病学について

背景:

乳がんはインドの女性の死因の1つで診断が遅れているのが一般的です
限られた資源と遅れた診断は低所得国や中所得国の生存率の低下に寄与しています
乳がんの予後改善には早期発見と手頃な治療が不可欠です

研究の目的:

早期乳がん (EBC) の患者の長期生存結果を評価する.
普遍的な健康保険 (UHC) 制度と統合された包括的な乳がんケアプログラムの有効性を評価する.
資源の限られた環境で乳がん管理戦略の改善のための証拠を提供すること.

主な方法:

2008年から2018年の間にUHC計画でEBCと診断された女性のコホート研究.
電子医療記録,診療所訪問,電話によるフォローアップ
測定された主なアウトカムは5年および10年全生存期および無疾患生存期でした.

主要な成果:

全乳がん患者の72. 8%を占めた185人のEBC患者が採用された.
平均生存期間は123ヶ月でした.
5年全生存率は85. 2%,10年全生存率は79. 0%でした. 無病生存率はそれぞれ84. 6%と76. 2%でした.

結論:

乳がんを早期発見するプログラムは患者の生存率を向上させるために不可欠です
UHCの枠組み内の総合的ながん治療は,全国の平均より高い生存率を達成することができます.
これらの発見は,インドや他のLMICで同様のプログラムを実施することを支持しています.

キーワード:

インド乳がん早期発見生存率普遍的な健康保険

さらに関連する動画

04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

13:35

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

2.9K

関連する概念動画

01:21

Cancer Survival Analysis

445

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

445

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

01:24

Kaplan-Meier Approach

254

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

254

01:20

Actuarial Approach

131

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

131

02:49

Cancer Therapies

7.9K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

7.9K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...